Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Brief Summary: This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also included.


Options:
A: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate placebo | Arm Label: Adalimumab + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Biological: Adalimumab placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Adalimumab + methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Adalimumab + methotrexate, Methotrexate | Intervention Type: BIOLOGICAL; Name: Adalimumab placebo; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Methotrexate placebo; Assigned to Arm(s): Adalimumab
B: Arm Label: CDP6038 60 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 60 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: CDP6038 120 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 120 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: CDP6038 240 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 240 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tocilizumab (Actemra or RoActemra), Other: Placebo sc | Arm Label: Placebo sc every 2 weeks plus methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo sc, Other: Placebo iv | Arm Label: Placebo sc every 4 weeks plus methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo sc, Other: Placebo iv | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 60 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 120 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 240 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: Tocilizumab (Actemra or RoActemra); Assigned to Arm(s): Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 60 mg sc every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 240 mg sc every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 120 mg sc every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo sc; Assigned to Arm(s): Placebo sc every 2 weeks plus methotrexate, Placebo sc every 4 weeks plus methotrexate, Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo sc; Assigned to Arm(s): CDP6038 120 mg sc every 4 weeks plus methotrexate, CDP6038 240 mg sc every 4 weeks plus methotrexate, CDP6038 60 mg sc every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo iv; Assigned to Arm(s): CDP6038 120 mg sc every 2 weeks plus methotrexate, CDP6038 120 mg sc every 4 weeks plus methotrexate, CDP6038 240 mg sc every 2 weeks plus methotrexate, CDP6038 240 mg sc every 4 weeks plus methotrexate, CDP6038 60 mg sc every 2 weeks plus methotrexate, CDP6038 60 mg sc every 4 weeks plus methotrexate, Placebo sc every 2 weeks plus methotrexate, Placebo sc every 4 weeks plus methotrexate
C: Arm Label: 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 | Arm Label: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biologic TNFi | Intervention Type: DRUG; Name: CP 690,550; Assigned to Arm(s): 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2 | Intervention Type: BIOLOGICAL; Name: Biologic TNFi; Assigned to Arm(s): adalimumab
D: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4

Answer: C